Targeting the cyp1b1 enzyme for radioactivity 18 f-labeled probe precursor

Abstract

The invention discloses a radioactive drug targeting CYP1B1 enzyme 18 F-labeled probe precursors; the probe precursors include affinity ligands that can be combined with CYP1B1 enzymes, and can be used for 18 The chelating group of F rapid label and the linking chain that is used to connect part and chelating group; The linking chain comprises multiple ethylene glycol fragments; The affinity part is α-naphthoflavone derivative, available At 18 The chelating group of F rapid labeling is 1,4,7-triazacyclononane-1,4-diacetic acid molecule. The present invention is a kind of CYP1B1 enzyme that can be combined with tumor-specific expression, and can be used for 18 F-labeled molecular probe precursor, after radiolabeling, can show the level of CYP1B1 enzyme in the tumor in PET imaging to visualize the tumor. The invention will effectively promote the application of molecular imaging technology in tumor diagnosis.

Description

technical field

[0001] The invention relates to the fields of PET imaging and tumor diagnosis, and relates to a radionuclide targeting CYP1B1 enzyme 18 F-labeled probe precursors; specifically one composed of ethylene glycol chains will be available for 18 The diagnostic reagent complex composed of F-labeled chelating groups and ligands that can specifically bind to cytochrome P450 1B1 enzymes is radioactive 18 F labeling allows visualization of tumors in PET imaging by showing levels of cytochrome P450 1B1 enzyme for tumor diagnosis. Background technique

[0002] Compared with traditional medical imaging, molecular imaging shows a better application prospect in the early diagnosis of tumors. Through the high-affinity enrichment effect of molecular probes on specific targets of tumor tissue, tumor imaging can be performed in the early stage of tumor occurrence or even before symptoms appear, and the effect of early diagnosis can be achieved. With the development of tumor ...

Images